Download PDF
Pharmacopsychiatry 2018; 51(06): 257-262
DOI: 10.1055/s-0043-125214
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Intramuscular Testosterone Supplementation Ameliorates Depression in Hypogonadal Men: A Retrospective Study in an Outpatient Department

Andrei Miclea
1   Neurological Outpatient Department, Neurozentrum Peine, Duttenstedter Strasse 11, 31224 Peine, Germany
2   Medical Faculty, Ruhr-University Bochum, Universitätsstrasse 150, 44801 Bochum, Germany
,
Marius Miclea
1   Neurological Outpatient Department, Neurozentrum Peine, Duttenstedter Strasse 11, 31224 Peine, Germany
,
Maximilian Pistor
2   Medical Faculty, Ruhr-University Bochum, Universitätsstrasse 150, 44801 Bochum, Germany
,
Katharina Stegmayer
3   Department of Neurology, University Hospital Bern and University of Bern, Freiburgstrasse, CH-3010 Bern, Switzerland
4   Translational Research Center, University Hospital of Psychiatry, Bern, Bolligenstrasse 111, CH-3072 Bern, Switzerland
,
Robert Hoepner
3   Department of Neurology, University Hospital Bern and University of Bern, Freiburgstrasse, CH-3010 Bern, Switzerland
› Author Affiliations
Further Information

Publication History

received 09 July 2017
revised 18 November 2017

accepted 13 December 2017

Publication Date:
01 February 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction Substantial evidence has indicated an association between hypogonadism and depressive symptoms, which led to the conduction of studies that found an ameliorating effect of testosterone (T) supplementation (S) upon depression in men.

Methods Retrospective analysis of medical records identified 16 depressed, hypogonadal men who have not responded adequately to initial antidepressant therapy and subsequently received intramuscular T injections. Following the proposal of Button et al., a minimal clinically important difference was defined as an 18% reduction of the Beck Depression Inventory-II (BDI-II) score.

Results After TS, the BDI-II score decreased by approximately 31% (p<0.01), from 27.2 (mean; standard deviation [SD] 11.8) to 18.8 (mean; SD 11.3). Patients with baseline BDI-II scores ranging from 29 to 63 (severe depression) showed a significantly higher absolute and relative reduction through TS. Also, men with a shorter depression duration (<2 years) demonstrated a greater benefit.

Conclusions The depressed, hypogonadal men generally benefited from TS given that the BDI-II score reduction was almost twice as much as needed for a minimal clinically important difference.

Key words

beck depression inventory - depression - hypogonadism - testosterone

Supporting Information

    Supporting Information for this article is available online https://doi.org/10.1055/s-0043-125214
  • Supporting Information
 

  • References

  • 1 Ebmaier KP, Donaghey C, Steele JD. Recent developments and current controversies in depression. Lancet 2006; 367: 153-167
    CrossrefPubMedGoogle Scholar
  • 2 Lima-Ojeda JM, Rupprecht R, Baghai TC. Neurobiology of depression: A neurodevelopmental approach. World J Biol Psychiatry 2017; 3: 1-33
    PubMedGoogle Scholar
  • 3 Lang UE, Borgwardt S. Molecular mechanisms of depression: Perspectives on new treatment strategies. Cell Physiol Biochem 2013; 31: 761-777
    CrossrefPubMedGoogle Scholar
  • 4 Mössner R, Mikova O, Koutsilieri E. et al. Consensus paper of the WFSBP Task Force on Biological Markers: Biological markers in depression. World J Biol Psychiatry 2007; 8: 141-174
    CrossrefPubMedGoogle Scholar
  • 5 Almeida OP, Waterreus A, Spry N. et al. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 2004; 29: 1071-1081
    CrossrefPubMedGoogle Scholar
  • 6 Barrett-Connor E, Von Mühlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: The Rancho Bernardo Study. J Clin Endocrinol Metab 1999; 84: 573-577
    CrossrefPubMedGoogle Scholar
  • 7 Kranz GS, Wadsak W, Kaufmann U. et al. High-dose testosterone treatment increases serotonin transporter binding in transgender people. Biol Psychiatry 2015; 78: 525-533
    CrossrefPubMedGoogle Scholar
  • 8 Perfalk E, Cunha-Bang SD, Holst KK. et al. Testosterone levels in healthy men correlate negatively with serotonin 4 receptor binding. Psychoneuroendocrinology 2017; 81: 22-28
    CrossrefPubMedGoogle Scholar
  • 9 Mahmoud R, Wainwright SR, Galea LA. Sex hormones and adult hippocampal neurogenesis: Regulation, implications, and potential mechanisms. Front Neuroendocrinol 2016; 41: 129-152
    CrossrefPubMedGoogle Scholar
  • 10 Stefansson J, Chatzittofis A, Nordström P. et al. CSF and plasma testosterone in attempted suicide. Psychoneuroendocrinology 2016; 74: 1-6
    CrossrefPubMedGoogle Scholar
  • 11 Book AS, Starzyk KB, Quinsey VL. The relationship between testosterone and aggression: A meta-analysis. Aggres Viol Behav 2001; 6: 579-599
    PubMedGoogle Scholar
  • 12 Wang C, Swerdloff RS, Iranmanesh A. et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000; 85: 2839-2853
    PubMedGoogle Scholar
  • 13 Burnham TC, Chapman JF, Gray PB. et al. Men in committed, romantic relationships have lower testosterone. Horm Behav 2003; 44: 119-122
    CrossrefPubMedGoogle Scholar
  • 14 Kratzik CW, Schatzl G, Lackner JE. et al. Mood changes, body mass index and bioavailable testosterone in healthy men: Results of the Androx Vienna Municipality Study. BJU Int 2007; 100: 614-618
    CrossrefPubMedGoogle Scholar
  • 15 Pope Jr HG, Amiaz R, Brennan BP. et al. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment. J Clin Psychopharmacol 2010; 30: 126-134
    CrossrefPubMedGoogle Scholar
  • 16 Pope Jr HG, Cohane GH, Kanayama G. et al. Testosterone gel supplementation for men with refractory depression: A randomized, placebo-controlled trial. Am J Psychiatry 2003; 160: 105-111
    CrossrefPubMedGoogle Scholar
  • 17 Seidman SN, Spatz E, Rizzo C. et al. Testosterone replacement therapy for hypogonadal men with major depressive disorder: A randomized, placebo-controlled clinical trial. J Clin Psychiatry 2001; 62: 406-412
    CrossrefPubMedGoogle Scholar
  • 18 Nian Y, Ding M, Hu S. et al. Testosterone replacement therapy improves health-related quality of life for patients with late-onset hypogonadism: A meta-analysis of randomized controlled trials. Andrologia 2017; 49: e12630
    CrossrefPubMedGoogle Scholar
  • 19 Corona G, Sforza A, Maggi M. Testosterone replacement therapy: Long-term safety and efficacy. World J Mens Health 2017; 35: 65-76
    CrossrefPubMedGoogle Scholar
  • 20 Minnemann T, Schubert M, Hübler D. et al. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate. Aging Male 2007; 10: 155-158
    CrossrefPubMedGoogle Scholar
  • 21 Seidman SN, Roose SP. The sexual effects of testosterone replacement in depressed men: Randomized, placebo-controlled clinical trial. J Sex Marital Ther 2006; 32: 267-273
    CrossrefPubMedGoogle Scholar
  • 22 Graubner B. ICD-10-GM 2013 Systematisches Verzeichnis: Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme 10. Revision – German Modification (Version 2013) Cologne, Germany: Deutscher Ärzte Verlag; 2012
    Google Scholar
  • 23 Beck AT, Steer RA, Brown GK. BDI-II Manual. San Antonio: The Psychological Corporation; 1996
    Google Scholar
  • 24 Dohle GR, Arver S, Bettocchi C. et al. Leitlinie Männlicher Hypogonadismus. J. Reproduktionsmed. Endokrinol 2013; 10: 279-292
    PubMedGoogle Scholar
  • 25 Button KS, Kounali D, Thomas L. et al. Minimal clinically important difference on the Beck Depression Inventory – II according to the patient’s perspective. Psychol Med. 2015; 45: 3269-3279
    CrossrefPubMedGoogle Scholar
  • 26 Seidman SN, Miyazaki M, Roose SP. Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men – randomized placebo controlled clinical trial. J Clin Psychopharmacol 2005; 25: 584-588
    CrossrefPubMedGoogle Scholar
  • 27 Holtzheimer 3rd PE, Russo J, Claypoole KH. et al. Shorter duration of depressive episode may predict response to repetitive transcranial magnetic stimulation. Depress Anxiety 2004; 19: 24-30
    CrossrefPubMedGoogle Scholar
  • 28 Safarinejad MR. Evaluation of endocrine profile and hypothalamic-pituitary-testis axis in selective serotonin reuptake inhibitor-induced male sexual dysfunction. J Clin Psychopharmacol 2008; 28: 418-423
    CrossrefPubMedGoogle Scholar
  • 29 Corona G, Ricca V, Bandini E. et al Selective serotonin reuptake inhibitor-induced sexual dysfunction. J Sex Med 2009; 6: 1259-1269
    CrossrefPubMedGoogle Scholar
  • 30 Farnia V, Shirzadifar M, Shakeri J. et al. Rosa damascena oil improves SSRI-induced sexual dysfunction in male patients suffering from major depressive disorders: Results from a double-blind, randomized, and placebo-controlled clinical trial. Neuropsychiatr Dis Treat 2015; 9: 625-635
    PubMedGoogle Scholar
  • 31 Jockenhövel F, Minnemann T, Schubert M. et al. Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood. Aging Male 2009; 12: 113-118
    CrossrefPubMedGoogle Scholar
  • 32 Goetz SM, Tang L, Thomason ME. et al. Testosterone rapidly increases neural reactivity to threat in healthy men: A novel two-step pharmacological challenge paradigm. Biol Psychiatry 2014; 76: 324-331
    CrossrefPubMedGoogle Scholar
  • 33 Reimers L, Büchel C, Diekhof EK. Neural substrates of male parochial altruism are modulated by testosterone and behavioral strategy. NeuroImage 2017; 156: 265-276
    CrossrefPubMedGoogle Scholar
  • 34 Lenze EJ, Mulsant BH, Shear MK. et al. Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: Results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry 2005; 162: 146-150
    CrossrefPubMedGoogle Scholar
  • 35 Kumsar Ş, Kumsar NA, Sağlam HS. et al. Testosterone levels and sexual function disorders in depressive female patients: Effects of antidepressant treatment. J Sex Med 2014; 11: 529-535
    CrossrefPubMedGoogle Scholar
  • 36 Kleeblatt J, Betzler F, Kilarski LL. et al. Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence. Eur Neuropsychopharmacol 2017; 27: 423-441
    CrossrefPubMedGoogle Scholar